FGFR2 and cancer: Through unbiased phenotypic screening using cancer growth inhibition as a functional readout, we selected 2 biparatopic antibody candidates that achieved highest efficacy in vitro and confirmed their therapeutic activities in FGFR2 fusion ICC xenograft models in vivo.